JO
CTNM

John Overdeck’s Contineum Therapeutics CTNM Stock Holding History

John Overdeck’s Portfolio CTNM Stock Details CTNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$497K Sell
30,347
-7,569
-20% -$99.2K ﹤0.01% 4164
2026
Q1 		$495K Hold
37,916
– – ﹤0.01% 3751
2025
Q4 		$433K Sell
37,916
-27
-0.1% -$308 ﹤0.01% 3391
2025
Q3 		$446K Sell
37,943
-23,020
-38% -$186K ﹤0.01% 3033
2025
Q2 		$242K Buy
+60,963
New +$265K ﹤0.01% 2859

Other funds holding CTNM

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

John Overdeck's CTNM Position: Q2 2026 in Review

John Overdeck reduced its Contineum Therapeutics (CTNM) stake by 20% in Q2 2026, selling an estimated $99.2K and leaving 30,347 shares worth $497K. The position accounts for ﹤0.01% of the portfolio, ranked #4164.

John Overdeck first reported a position in CTNM in Q2 2025 and has held it in 5 quarters since. 101 funds tracked by Wall St. Rank hold CTNM as of Q2 2026.

  • John Overdeck held 30,347 shares of Contineum Therapeutics worth $497K as of Q2 2026.
  • John Overdeck sold 7,569 Contineum Therapeutics shares in Q2 2026, an estimated $99.2K.
  • Contineum Therapeutics made up ﹤0.01% of John Overdeck's portfolio in Q2 2026, its #4164 holding.
  • John Overdeck first reported a position in Contineum Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • 101 funds tracked by Wall St. Rank held Contineum Therapeutics as of Q2 2026.

Based on Two Sigma Investments's 13F filing for Q2 2026, filed 14 Aug 2026.